GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Linezolid

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordAll source differencesRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

UCSF - linezolid: standard dose and optional expert reduction

Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method
CrCl in mL/min where specified; no equation inferred.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Label guidance versus selected expert dose reduction

The label does not require routine renal reduction. UCSF describes a selected strategy for stable patients with CrCl below 30 and an anticipated course longer than 10 days, after the initial 72 hours.

What to reconcile: Do not apply a reduced regimen universally. Retain the clinical-stability, duration, monitoring and specialist qualifiers.

Source difference identified; final patient-specific adjudication required.

Open this note and its source references

Linezolid: qualified expert reduction versus label no-adjustment

UCSF describes an optional expert reduction for selected stable patients receiving a prolonged course, rather than a universal renal reduction. Its dialysis table remains separately stated.

What to reconcile: Document the source and qualifying clinical context; involve infectious diseases and consider drug-level monitoring. Do not apply the expert exception indiscriminately.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Professional

UCSF - linezolid: standard dose and optional expert reduction

Open original reference

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Usual adult treatment is 600 mg IV or orally every 12 hours without routine renal adjustment; the hemodialysis table retains that regimen. Mycobacterial infection uses a separate 600 mg daily regimen.

For clinically stable patients with CrCl <30 mL/min and anticipated therapy longer than 10 days, some experts consider 300 mg twice daily after the first 72 hours to lower thrombocytopenia risk. This is an optional specialist-guided strategy, not a universal renal dose. Therapeutic drug monitoring may help; involve infectious diseases/pharmacy.

RDM30-018-linezolid-1 · Source locator: UCSF - linezolid: standard dose and optional expert reduction; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/linezolid
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
8e262bea091d636586d5af87ee33b56cb6ce884096a3590b47fd80caa61167e5

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=linezolid&s1=RDM30-018-linezolid&h1=42953a7f605bac6f53f926d84d182938726e0ed4df7ea95b30923a09a6bad540